REGENXBIO Inc. (RGNX) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-438.7%

-$24.25

vs $7.16 price

Levered DCF

-$26.74

After debt service

Piotroski score

2 / 9

Weak

Altman Z-score

-3.81

Distress zone

Rating

D+

Overall 1 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	-3.83×	-1.68×	-2.98×	-3.49×	10.86×	-15.22×	-15.88×	15.37×
P/B	7.23×	1.47×	2.52×	1.9×	1.82×	4.48×	3.34×	3.02×
P/S	4.36×	4.59×	8.7×	8.68×	2.95×	10.94×	42.66×	7.03×
EV / EBITDA	-7.27×	-2.05×	-3.51×	-4×	6.38×	-14.72×	-16×	15.92×
Gross margin	88.1%	59.7%	58.8%	51.6%	89.0%	76.9%	76.6%	95.6%
Operating margin	-94.6%	-280.0%	-297.1%	-233.2%	34.0%	-77.1%	-422.9%	40.3%
Net margin	-113.8%	-272.5%	-292.0%	-248.7%	27.2%	-72.0%	-268.9%	45.7%
Current ratio	2.38×	2.69×	2.57×	3.19×	3.98×	6.52×	10.25×	15.24×
Debt / equity	2.54×	0.32×	0.29×	0.18×	0.11×	0.19×	0.03×	0.01×
Interest coverage	-3.58×	-18.43×	-39.07×	-11.3×	6.09×	-154.65×	0×	0×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	-188.7%	-87.5%	-84.5%	-54.3%	16.7%	-29.5%	-21.0%	19.6%
Return on invested capital	-42.1%	-62.9%	-59.4%	-37.1%	14.7%	-18.9%	-31.0%	16.2%
Return on assets	-42.8%	-48.7%	-45.9%	-33.6%	11.5%	-15.7%	-19.0%	18.4%
Free cash flow yield	-17.0%	-45.9%	-29.1%	-24.3%	9.7%	-4.8%	-7.9%	5.9%
Earnings yield	-26.1%	-59.3%	-33.6%	-28.6%	9.2%	-6.6%	-6.3%	6.5%
Enterprise value	$968.7M	$407.2M	$839.8M	$976.5M	$1.1B	$1.4B	$1.4B	$1.5B
Net debt / EBITDA	-1.7×	-0.12×	-0.23×	0.01×	-1.46×	2.74×	0.64×	-0.76×
Cash conversion cycle (days)	-325	-153	-117	-84	-55	100	111	64